IN2013MU03610A - - Google Patents

Info

Publication number
IN2013MU03610A
IN2013MU03610A IN3610MU2013A IN2013MU03610A IN 2013MU03610 A IN2013MU03610 A IN 2013MU03610A IN 3610MU2013 A IN3610MU2013 A IN 3610MU2013A IN 2013MU03610 A IN2013MU03610 A IN 2013MU03610A
Authority
IN
India
Prior art keywords
dasatinib monohydrate
abstract
commercially
describes
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Guruprasad Ramchandra Wader
Dharmesh Mahendrabhai Shah
Original Assignee
Dharmesh Mahendrabhai Shah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dharmesh Mahendrabhai Shah filed Critical Dharmesh Mahendrabhai Shah
Priority to IN3610MU2013 priority Critical patent/IN2013MU03610A/en
Priority to PCT/IN2014/000782 priority patent/WO2015107545A1/en
Publication of IN2013MU03610A publication Critical patent/IN2013MU03610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
IN3610MU2013 2013-12-18 2014-12-17 IN2013MU03610A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3610MU2013 IN2013MU03610A (es) 2013-12-18 2014-12-17
PCT/IN2014/000782 WO2015107545A1 (en) 2013-12-18 2014-12-17 Water soluble salts of dasatinib hydrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3610MU2013 IN2013MU03610A (es) 2013-12-18 2014-12-17

Publications (1)

Publication Number Publication Date
IN2013MU03610A true IN2013MU03610A (es) 2015-04-24

Family

ID=53039939

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3610MU2013 IN2013MU03610A (es) 2013-12-18 2014-12-17

Country Status (2)

Country Link
IN (1) IN2013MU03610A (es)
WO (1) WO2015107545A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
HRP20151051T1 (hr) 2005-05-05 2015-11-06 Bristol-Myers Squibb Holdings Ireland Formulacije src/abl inhibitora
WO2006135790A1 (en) 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
US20070105867A1 (en) 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
WO2010139979A2 (en) * 2009-06-03 2010-12-09 Generics [Uk] Limited Processes for preparing crystalline forms
NZ630288A (en) * 2012-04-20 2015-08-28 Shilpa Medicare Ltd Process for preparing dasatinib monohydrate

Also Published As

Publication number Publication date
WO2015107545A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
PH12016500169A1 (en) Polymorph of syk inhibitors
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IN2013MU00646A (es)
IN2014MU00455A (es)
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
IN2013MU03862A (es)
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
IN2013MU01111A (es)
IN2013MU01113A (es)
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IN2014CH00304A (es)
PL2964607T3 (pl) Sposób wytwarzania halogeno-n,n-dimetylobenzyloamin
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
IN2013MU04056A (es)
PT2981518T (pt) Um processo melhorado para a preparação de maleato de fluvoxamina
HUP1400104A2 (en) Compositions comprising indometacine, its pharmaceutically acceptable salts and cocrystals; and process for the preparation
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2013CH04314A (es)
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
IN2013MU03565A (es)
MX369008B (es) Un proceso mejorado para la preparación de exametazima.
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2014CH01391A (es)